Autoimmune CAR-Ts Under Scrutiny Following Cabaletta’s Safety Concerns in Lupus Treatment
Autoimmune CAR-T, Cabaletta, Lupus, Safety Concerns, Clinical Trials
Alfasigma’s PBC Treatment Ocaliva to Face FDA Advisory Committee in September
Alfasigma, Ocaliva, PBC, FDA advisory committee, primary biliary cholangitis, liver disease treatment
FDA Criticizes Bristol Myers Squibb for Misleading Efficacy Claims on Krazati Website
Bristol Myers Squibb, FDA, Krazati, misleading efficacy claims, non-small-cell lung cancer, NSCLC, KRAS G12C-mutated, cancer treatment
Novartis’ Fabhalta Clinches Another FDA Win, This Time in IgA Nephropathy
Novartis, Fabhalta, FDA approval, IgA nephropathy, proteinuria reduction, complement inhibitor, kidney disease
Gilead Sciences Exceeds Q2 Expectations, Boosts Optimism for Seladelpar Decision
Gilead Sciences, Q2 earnings, seladelpar, PBC, liver disease, financial performance, pharmaceuticals
SandboxAQ and Mayo Clinic Partner to Revolutionize Cardiac Diagnostics with AI-Powered Magnetocardiography
SandboxAQ, Mayo Clinic, AI-powered magnetocardiography, cardiac diagnostics, CardiAQ, medical imaging technology, quantum sensors, large quantitative models
Hims Secures Drug Supply for Thriving Weight Loss Business
Hims, weight loss drugs, compounded GLP-1, drug supply, booming business, revenue growth, subscriber base
Entero Therapeutics Faces Financial Struggles, Lays Off Most Staff Amidst Debt Crisis
Entero Therapeutics, financial struggles, layoffs, debt crisis, creditors, strategic alternatives
Apellis and Sobi Achieve Significant Breakthrough in Phase 3 Trial for Rare Kidney Disease Treatment
Apellis Pharmaceuticals, Sobi, pegcetacoplan, Phase 3 VALIANT study, C3 glomerulopathy, primary immune complex membranoproliferative glomerulonephritis, proteinuria reduction, kidney disease treatment, FDA approval, European Medicines Agency
IDRx Secures $120M for Pivotal KIT Inhibitor Study with Promising Early Data
IDRx, KIT inhibitor, pivotal study, funding, cancer treatment, biotech